Cyprotex to expand Boston, US facility
Driven by strong demand for the specialist in vitro toxicology services offered at the facility
Cyprotex, a provider of preclinical ADME-Tox services, is to expand its US facility in Watertown, Boston, MA, from 4,400ft2 to 8,200ft2.
The firm, which also has laboratories in Macclesfield, Cheshire, UK, said the expansion has been driven by strong demand in North America for its services and an increasing worldwide demand for the specialist in vitro toxicology services provided by the Watertown facility, in particular, Cyprotex’s CellCiphr High Content Toxicology service.
The US facility was acquired as part of the August 2010 purchase of Apredica. Since then revenues for the facility have more than doubled and are continuing to increase steadily.
In the first half of 2011, revenues for the US site were £1.27m compared with £0.53m for the same period in 2010.
Tony Baxter, Cyprotex’s chief executive, said: ‘Cyprotex’s increasingly acute need to expand the Watertown facility is the consequence of a series of successful strategic efforts, including our entry into the in vitro toxicology market. In 2011, we have continued to focus on growth, most recently with the launch of our genomic ADME service, gADME, which allows tailored dosage regimens of drugs based on genetics. This new service opens new commercial possibilities for compounds that historically may have had to be discontinued from development.’
Katya Tsaioun, Cyprotex’s chief scientific officer, added: ‘Our extended facilities will allow us to be at the forefront of applying in vitro technologies to the toxicity problem, which we believe will be the greatest efficiency improvement of this decade.’
